Phasostabil, 75 mg+15, 2 mg 100 pcs

The mechanism of action of acetylsalicylic acid (ASA) is based on irreversible inhibition of cyclooxygenase (COX-1), resulting in blocked synthesis of thromboxane A2 and suppressed platelet aggregation. It is believed that ASA has other mechanisms to inhibit platelet aggregation, which expands the field of its use in various vascular diseases.

ASK also has anti-inflammatory, analgesic and antipyretic effects. The anti-inflammatory effect is associated with decreased blood flow due to inhibition of prostaglandin E2 synthesis.

Magnesium hydroxide, which is part of the drug Fasostabil, has an antacid effect and protects the mucous membrane of the gastrointestinal tract from the effects of ASA.

Indications

Active ingredient

Composition

How to take, the dosage

Interaction

Special Instructions

The drug should be used as prescribed by a physician.

ASK may provoke bronchospasm, as well as cause attacks of bronchial asthma and other hypersensitivity reactions. Risk factors include a history of bronchial asthma, hay fever, nasal polyposis, chronic respiratory disease, and allergic reactions to other medications (e.g., skin reactions, itching, urticaria).

ASA can cause bleeding of varying severity during and after surgical interventions.
Several days before the planned surgical intervention, the risk of bleeding should be assessed compared to the risk of ischemic complications in patients taking low-dose ASA. If the risk of bleeding is significant, ASA should be temporarily stopped.

The concomitant use of ASA with anticoagulants, thrombolytics and antiplatelet agents is accompanied by an increased risk of bleeding.

. Caution should be exercised in cases of impaired renal function (CK greater than 30 ml/min), as well as in circulatory disorders due to atherosclerosis of the renal arteries, chronic heart failure, extensive surgery, sepsis, cases of massive bleeding, since in all the above cases ASA may increase the risk of acute renal failure/renal function impairment.

It is known that the risk of acute renal failure increases when other NSAIDs are used together with ACE inhibitors or diuretics.

In patients with mild to moderate hepatic impairment, liver function should be monitored regularly.

ASK at low doses may provoke the development of gout in predisposed patients (who have decreased uric acid excretion).

Combination of Asc and methotrexate is accompanied by increased incidence of side effects from the hematopoietic organs, concomitant use with valproic acid increases the risk of its toxicity. During the first weeks of concomitant administration of Fazostabil and methotrexate in dose less than 15 mg weekly, a weekly blood test should be performed. Even in case of small renal dysfunctions and in elderly patients careful monitoring is necessary.

Simultaneous administration of ASA with anticoagulants, thrombolytics and antiplatelet agents is associated with increased risk of bleeding and damaging effect on mucosa of gastrointestinal tract.

The concomitant use of Fazostabil with ibuprofen in patients with increased risk of cardiovascular events is not recommended because the reduction of the antiplatelet effect of ASA at doses up to 300 mg will decrease the cardioprotective effects. Patients taking ibuprofen for pain relief should inform their physician about this.

Monitoring of plasma concentrations of digoxin and lithium at the beginning or at the end of concomitant use of Fazostabil is recommended; dose adjustment may be required.

When concomitant use with diuretics and hypotensive agents (e.g., ACE inhibitors) a possible decrease of their effectiveness should be considered.

High doses of Asc have hypoglycemic effect, and this must be considered when prescribing it for patients with diabetes mellitus who receive oral hypoglycemic agents and insulin.

When concomitant use of systemic glucocorticosteroids and salicylates, it should be remembered that during treatment the concentration of salicylates in blood is reduced, and after cancellation of systemic glucocorticosteroids an overdose of salicylates is possible. With long-term use of low doses of ASA as antiplatelet therapy care must be taken in elderly patients because of the risk of gastrointestinal bleeding.

In long-term use of Fazostabil it is necessary to periodically control general blood count and stool test for occult blood as well as functional state of liver.

In concomitant use of ASA with alcohol, there is an increased risk of gastrointestinal mucosal damage and prolongation of bleeding time.

In severe forms of glucose-6 phosphate dehydrogenase deficiency, ASK may cause hemolysis and hemolytic anemia. Factors that increase the risk of hemolysis and hemolytic anemia are fever, acute infections, and high doses of ASA.

When treating with Fasostabil it is necessary to be careful when driving vehicles and engaging in potentially dangerous activities requiring increased concentration and rapid psychomotor reaction.

Contraindications

Side effects

Overdose

Similarities